Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer. Issue 1 (13th February 2023)

• Record Type: Journal Article
• Authors: Tohi, Makiko; Irie, Kei; Mizuno, Tomoyuki; Okuyoshi, Hiroyuki; Hirabatake, Masaki; Ikesue, Hiroaki; Muroi, Nobuyuki; Eto, Masaaki; Fukushima, Shoji; Tomii, Keisuke; Hashida, Tohru
• Is Part Of: Therapeutic drug monitoring. Volume 45:Issue 1(2023)
• Page Start: 110
• Page End: 116
• Publication Date: 2023-02-13
• Subjects: nivolumab -- population pharmacokinetics -- real-world data -- nonsmall cell lung cancer; Pharmacokinetics -- Periodicals; Patient monitoring -- Periodicals; Drugs -- Analysis -- Periodicals; Body fluids -- Analysis -- Periodicals; Drug Therapy -- Periodicals; Monitoring, Physiologic -- Periodicals; Pharmacology -- Periodicals; 615.7
• DOI: 10.1097/FTD.0000000000000996
• Languages: English
• ISSNs: 0163-4356

Abstract

Abstract : Supplemental Digital Content is Available in the Text. Abstract : Background: Nivolumab is an antiprogrammed death-1 (PD-1) antibody used for immuno-oncological therapy of various cancers, including nonsmall cell lung cancer (NSCLC). This study aimed to characterize the real-world population pharmacokinetics (PK) of nivolumab in patients with NSCLC. Methods: PK samples were collected by opportunistic sampling of Japanese patients with NSCLC treated with nivolumab monotherapy. Population PK analysis was performed using a two-compartment model in Nonlinear Mixed Effect Model. Patient-specific factors such as body weight, age, sex, serum albumin, estimated glomerular filtration rate, performance status, programmed cell death receptor ligand 1 expression in tumors, and treatment periods were evaluated as potential covariates for clearance. Results: A total of 223 serum samples collected from 34 patients were available for analysis. The median (min–max) age and weight were 69 years (38–83 years) and 62.7 kg (36.8–80.5 kg), respectively. The mean (95% confidence interval) clearance estimate was 0.0064 L/h (0.0058–0.0070 L/h). The inclusion of the ALB level, estimated glomerular filtration rate, and treatment period significantly improved the model fit. Conclusions: A real-world nivolumab population PK model was developed using an opportunistic sampling strategy in Japanese patients with NSCLC. Further studies are warranted to characterize the exposure–response relationship and determine the optimal dosing regimens for these patients.